JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preston, K. L.
Right arrow Articles by Bigelow, G. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preston, K. L.
Right arrow Articles by Bigelow, G. E.

Vol. 295, Issue 1, 114-124, October 2000

Effects of Agonist-Antagonist Opioids in Humans Trained in a Hydromorphone/Not Hydromorphone Discrimination1

Kenzie L. Preston2 and George E. Bigelow

Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland

The purpose of this study was to examine the discrimination of agonist-antagonist opioids in humans trained in a two-choice hydromorphone/not hydromorphone discrimination. Eight adult male volunteers with histories of opioid abuse who were not currently physically dependent were trained to discriminate the mu receptor agonist hydromorphone (3 mg/70 kg, i.m.) ("Drug A") from a "Not Drug A" training condition (saline placebo). Volunteers received financial reinforcement for correct responses. After training, generalization dose-effect curves for hydromorphone, butorphanol, pentazocine, nalbuphine, and buprenorphine were determined. Other subjective, behavioral, and physiological measures were concurrently collected in all sessions. In generalization testing hydromorphone and buprenorphine produced dose-related increases in hydromorphone-appropriate responses. Pentazocine produced an inverted U-shaped dose-response curve with complete substitution at 32 mg/70 kg but not at 64 mg/70 kg. Butorphanol and nalbuphine did not completely substitute for hydromorphone at any dose tested. These results differ from an earlier two-choice, Drug A versus Drug B (hydromorphone/saline) discrimination study. After Drug/Not Drug instructions the behavioral discriminations of agonist-antagonist opioids were more consistent with their putative agonist activities at the mu opioid receptor and with their subjective effects profiles than was the case after Drug A versus Drug B instructions. These results suggest that instructions are an important factor in the outcome of human drug discrimination studies.


1 The work was supported by United States Public Health Service Research Grants DA-04089 and Research Scientist Award DA-00050 from the National Institute on Drug Abuse.

2 Dr. Preston is currently supported by funds from the National Institute on Drug Abuse Intramural Research Program.


0022-3565/00/2951-0114$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by U.S. Government



This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
J. Fichna, A. Janecka, J. Costentin, and J.-C. Do Rego
The Endomorphin System and Its Evolving Neurophysiological Role
Pharmacol. Rev., March 1, 2007; 59(1): 88 - 123.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. D. Comer, M. A. Sullivan, and E. A. Walker
Comparison of Intravenous Buprenorphine and Methadone Self-Administration by Recently Detoxified Heroin-Dependent Individuals
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1320 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Behav Cogn Neurosci RevHome page
T. H. Kelly, W. W. Stoops, A. S. Perry, M. A. Prendergast, and C. R. Rush
Clinical Neuropharmacology of Drugs of Abuse: A Comparison of Drug-Discrimination and Subject-Report Measures
Behav Cogn Neurosci Rev, December 1, 2003; 2(4): 227 - 260.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.